Angina (Angina Pectoris) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Angina (Angina Pectoris) – Pipeline Review, H1 2017’, provides an overview of the Angina (Angina Pectoris) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Angina (Angina Pectoris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Angina (Angina Pectoris) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris)

The report reviews pipeline therapeutics for Angina (Angina Pectoris) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Angina (Angina Pectoris) therapeutics and enlists all their major and minor projects

The report assesses Angina (Angina Pectoris) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Angina (Angina Pectoris)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Angionetics Inc

Juventas Therapeutics Inc

Kuhnil Pharmaceutical Co Ltd

Lee's Pharmaceutical Holdings Ltd

Sanofi

Shire Plc

TSH Biopharm Corporation Ltd

ViroMed Co Ltd

XyloCor Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Angina (Angina Pectoris) - Overview

Angina (Angina Pectoris) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Angina (Angina Pectoris) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Angina (Angina Pectoris) - Companies Involved in Therapeutics Development

Amgen Inc

Angionetics Inc

Juventas Therapeutics Inc

Kuhnil Pharmaceutical Co Ltd

Lee's Pharmaceutical Holdings Ltd

Sanofi

Shire Plc

TSH Biopharm Corporation Ltd

ViroMed Co Ltd

XyloCor Therapeutics Inc

Angina (Angina Pectoris) - Drug Profiles

alferminogene tadenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EG-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erenumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JVS-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KI-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ranolazine ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAR-407899 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XC-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Angina (Angina Pectoris) - Dormant Projects

Angina (Angina Pectoris) - Discontinued Products

Angina (Angina Pectoris) - Product Development Milestones

Featured News & Press Releases

Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease

Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease

May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum

Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease

May 16, 2012: Ark Completes Dose Ranging Phase I Section Of Refractory Angina Clinical Study

Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program

Jan 28, 2010: First Refractory Angina Patient Treated With VEGF-D Shortform (EG011) In Phase I/IIa Trial

Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Angina (Angina Pectoris), H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Angina (Angina Pectoris) – Pipeline by Amgen Inc, H1 2017

Angina (Angina Pectoris) – Pipeline by Angionetics Inc, H1 2017

Angina (Angina Pectoris) – Pipeline by Juventas Therapeutics Inc, H1 2017

Angina (Angina Pectoris) – Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017

Angina (Angina Pectoris) – Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Angina (Angina Pectoris) – Pipeline by Sanofi, H1 2017

Angina (Angina Pectoris) – Pipeline by Shire Plc, H1 2017

Angina (Angina Pectoris) – Pipeline by TSH Biopharm Corporation Ltd, H1 2017

Angina (Angina Pectoris) – Pipeline by ViroMed Co Ltd, H1 2017

Angina (Angina Pectoris) – Pipeline by XyloCor Therapeutics Inc, H1 2017

Angina (Angina Pectoris) – Dormant Projects, H1 2017

Angina (Angina Pectoris) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Angina (Angina Pectoris) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Angina (Angina Pectoris), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports